Results 81 to 90 of about 122,751 (340)

Comparative Evaluation of Antimicrobial Activity of 0.2% Lemongrass Oil and 0.2% Chlorhexidine as a Preprocedural Mouth Rinse: A Randomised Controlled, Parallel Design, Split-mouth Clinical Trial [PDF]

open access: yesJournal of Clinical and Diagnostic Research
Introduction: The aerosols produced by an ultrasonic scaler contain bacteria that may enter the respiratory systems of both dental surgeons and patients.
Gautami S Penmetsa   +5 more
doaj   +1 more source

Anti-infectives in Drug Delivery-Overcoming the Gram-Negative Bacterial Cell Envelope. [PDF]

open access: yes, 2017
Infectious diseases are becoming a major menace to the state of health worldwide, with difficulties in effective treatment especially of nosocomial infections caused by Gram-negative bacteria being increasingly reported.
A Davin-Regli   +76 more
core   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii [PDF]

open access: yes, 2014
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Betts, JW, Wareham, DW
core   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

MEDICAL PROTECTION FOR THE EXPEDITIONARY FORCE IN THE EVENT OF USING BIOLOGICAL AGENTS [PDF]

open access: yesAnnals: Series on Military Sciences, 2014
The ADM/CBRN military or terrorist attack is most likely to be enforced on the force deployed in the theaters of operations (TO), as peace making troops, peace keeping troops, etc.
Viorel ORDEANUL   +2 more
doaj  

Nutraceutical Role of Polyphenols and Triterpenes Present in the Extracts of Fruits and Leaves of Olea europaea as Antioxidants, Anti-Infectives and Anticancer Agents on Healthy Growth [PDF]

open access: gold, 2022
Eva E. Rufino‐Palomares   +6 more
openalex   +1 more source

Human infection with Gongylonema pulchrum [PDF]

open access: yes, 1994
A 43 year old woman developed a painful tumor at the left buccal mucosa. Following local anti-inflammatory treatment a 35 mm long, living female adult worm of Gongylonema pulchrum was extracted from the affected side.
Jelinek, Thomas, Löscher, Thomas
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy